Since the discovery of THC, the medical industry has been interested in studying the interactions between cannabinoids and the human endocannabinoid system (ECS). Synthetic cannabinoids (SCBs) have been developed to mimic the effects of natural cannabinoids, with thousands of compounds created. These chemicals have different structures and a higher affinity for ECS receptors, making them more potent than natural cannabinoids. They have been used in pharmacological studies and show potential for treating various medical conditions. However, they also have drawbacks such as unpredictable side effects and a higher risk for abuse.